Sep 28, 2026
Merck (MRK) Secures Exclusive Rights to Cancer Drug in $2.13B SciBrunch Agreement
Merck (MRK) acquires worldwide rights to SPR2015 cancer drug from SciBrunch in deal valued at $2.13B, targeting common KRAS G12D mutation.
The post Merck (MRK) Secures Exclusive Rights to Cancer Drug in $2.13B SciBrunch Agreement appeared first on Blockonomi.
Source: Blockonomi →Related News
- 2 hours ago
Hyperliquid Strategies Inc. (PURR) Stock: Shares Climb as Company Boosts Buyback...
- 2 hours ago
Ionis Pharmaceuticals (IONS) Stock: Falls 2.23% Despite Roche’s Breakthrough Pha...
- 3 hours ago
Hyperscale Data, Inc. (GPUS) Stock: Soars 34% as Michigan AI Data Center Nears D...
- 4 hours ago
Edible Garden AG (EDBL) Stock Falls Despite New Farm Partnership Targeting 19% G...
- 7 hours ago
Rocket Lab (RKLB) Stock: Surges as Electron Completes 98th Launch for HawkEye 36...